Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromosome 22 open reading frame 31 (C22orf31) encodes a protein of 290 amino acids with a predicted molecular mass of 33 kDa and a basic isoelectric point. The protein encompasses a large region identified as “domain of unknown function 4662” (DUF4662), for which neither structure nor specific biological role has been established. C22orf31 shows moderate expression in the testes, low expression in brain and ovaries, and some presence in cancer cell lines. Post-translational modifications such as O-glycosylation, glycation, phosphorylation, and O-GlcNAcylation are predicted. The gene is not associated with well-defined molecular pathways or disease mechanisms, nor is it linked to any known drug interactions or therapeutic targeting. Overall, C22orf31 remains uncharacterized with respect to molecular function and clinical significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome 22 open reading frame 31 (C22orf31).